Read the committee members' biographies and registered interests.
Dr Amanda Adler MD, PhD, FRCP
Consultant Physician, Addenbrooke's Hospital
Amanda Adler trained in economics, medicine and epidemiology and is a consultant physician with an interest in diabetes at Addenbrooke's Hospital, Cambridge. Other roles include honorary clinical epidemiologist in the MRC Epidemiology Unit, Institute of Metabolic Sciences, Cambridge and research associate, Diabetes Trials Unit, Oxford. Previous roles include Clinical Epidemiologist, UK Prospective Diabetes Study, advisor, UK National Screening Committee, and physician, University of Washington, Seattle. She chaired the NICE committee addressing Newer Agents for Blood Glucose Control in Type 2 Diabetes.
Dr Sanjeev Patel BM DM FRCP
Consultant Physician and Senior Lecturer in rheumatology
Sanjeev's clinical duties include acute intaking medicine and rheumatology services with a special interest in bone diseases. He is Chair of the Medicines Management Committee of the Trust and Chair of the Rheumatology Speciality Advisory Committee to the Royal College of Physicians. His current research interests include the role of vitamin D in chronic diseases, and studies of secondary causes of osteoporosis and fractures, such as anorexia nervosa and chronic kidney disease.
Dr Carlo Berti
Consultant Psychiatrist and Hon. Lecturer, Kent and Medway Partnership Trust
Biography to follow
Non-financial professional and personal interest
Ministry of Defence, novel psychoactive substnces expert, fee paying service.
Dr Laura Bojke
Reader in Health Economics, Centre for Health Economics, University of York
Laura joined the team for economic evaluation and health technology assessment in 1999. She completed her PhD at York in 2008, titled 'Characterising structural uncertainty within decision analytic models’. She has worked on a number of projects involving the use of expert elicited data within decision analytic models and is particularly interested in this area and its application to issues of extrapolation uncertainty.
Laura has worked on a wide range of applied and methodological projects and has gained extensive experience of modelling the cost-effectiveness of arthritis and musculoskeletal diseases, especially psoriatic arthritis.
Laura is currently working on the Collaboration for Leadership in Applied Research and Care (CLAHRC) for Yorkshire and Humber as part of the Health Economics and Outcomes Measurement team. The program of work includes the use of economic evaluation across sectors, economic evaluation for local decision makers and the use of routine data for economic evaluation. Laura contributes to a range of short courses ran at CHE and leads the Assessing the Impact of Medical Technologies on Health module as part of the distance learning MSc in Economic Evaluation for Health Technology Assessment. She is also a member of the Research for Patient Benefit panel for Yorkshire and Humber. Laura is a member of the equality and diversity action group and was a member of the Athena swan group prior to this.
Professor John Cairns
Professor of Health Economics Public Health and Policy, London School of Hygiene and Tropical Medicine
John Cairns is a graduate in Economics of the Universities of Aberdeen and York. He is currently Professor of Health Economics in the department of Public Health and Policy, at the London School of Hygiene and Tropical Medicine. He is a member of the Health Technology Assessment Commissioning Board, the Scottish Medicines Consortium and Advisory Committee on the Safety of Blood, Tissues and Organs.
Direct - financial
April 2017 to May 2017: payment for preparatory work and travel time for participation in a value based cancer workshop. The contractor was Boehringer Ingelheim, Middle East & North Africa Scientific Office. Presented a lecture entitled assessing the cost-effectiveness of treatments for non-small cell lung cancer. The focus was on the 20+ appraisals NICE have conducted in this area rather than on any particular BI products.
March 2018 to March 2018: payment for participating in a ‘Multi Criteria Decision Analysis workshop’ The Contractor was LSE Enterprise Ltd. The workshop focused on NASH compounds and was funded by Novartis Pharma AG.
Mr Mark Chapman
Director, Health Economics & Commissioning Medtronic UK & Ireland
Mark has been with Medtronic since 2001. He currently heads the health economics team where he is responsible for Medtronic’s strategies as related to health economics, economic regulator submissions and associated clinical study design as related to the quantification of cost and effectiveness. Prior to joining Medtronic, he trained as a Clinical Physiologist, and worked for 11 years within the NHS tertiary cardiac care, with a specialist interest in complex cardiac devices.
Mark is a past member of the external advisory board and the University of Leeds EPSRC Centre for Innovative Manufacturing of Medical Devices. He has undertaken secondments within the UK Government, Office for Life Science, Department of Business, as Med Tech Policy Advisor, supporting the work of the UK Life Sciences Strategy.
Mark holds a BSc (hons) in Applied Biological Sciences and a Post Graduate Diploma in Health Economics. He received his MBA from Keele University, School of Public Policy.
Direct - financial
2001 to present: employee of Medtronic Ltd.
Dr Susan Faulds
Principle teaching Fellow, University of Southampton
Susan is a Principle Teaching Fellow and Director of Postgraduate Taught programmes in the Faculty of Health Sciences at the University of Southampton. As a registered nurse, Susan’s background is critical care medicine and her teaching and research reflects this.
September 2003 to present: employee of University of Southampton.
Dr Mark Glover
MRC Clinician Scientist, Associate Professor and Honorary Consultant Physician, University of Nottingham
Mark trained in pre-clinical pharmacology and clinical medicine at Gonville and Caius College, Cambridge. He is a Clinical Pharmacologist and General Physician at the University of Nottingham and Nottingham University Hospitals NHS Trust. His clinical and research interests are in hypertension. Mark leads the hypertension service in Nottingham and leads an MRC funded research group focused on the molecular pathophysiology of sodium reabsorption in the distal nephron in Thiazide Induced Hyponatraemia and Gordon syndrome.
Mark is a member of the Prescribing Safety Assessment Board for UK medical students, and a member of the NICE hypertension in adults guideline committee.
Mr Gareth Hooper
Methodologist, Oxford Academic Health Science Network
Gareth's role is to look at how new and innovative technologies can be introduced into the NHS.
He originally trained in Environmental Health and specialised in the effects of air pollution and noise on health. He later moved into public health commissioning where he led a multi-agency project to look at the effect of health inequalities on individuals living in deprived areas and the efficacy of interventions to improve health outcomes. In 2016 he moved to Gloucestershire CCG as a commissioner and was part of a team developing Primary Care Networks. Before he left the CCG in 2019, he led the commissioning for physical disabilities across Gloucestershire Integrated Care System.
Gareth holds an MSc in Health Economics and Health Policy from the University of Birmingham.
Dr Megan John
General Practitioner, Forest Health Group
Megan is a GP partner of a group of practices which provide primary and community care services to patients in Berkshire. She has an interest in medical research and supports this within her practices through the Thames valley research group.
She is also the clinical lead for Thames Valley policy and protocols committee, Individual Funding Request lead and does consulting for CCGs and other bodies on performance and related issues for practices and trusts and other contract holding services. She served on the NIHR late stage funding panel for 5 years.
Megan has a mainly medical background, with special interest in altitude and wilderness medicine, family planning and dementia, for which she also leads locality teams. She also has a degree in Business Management.
Dr Sanjay Kinra
Reader in Clinical Epidemiology and Honorary Consultant in Paediatrics, London School of Hygiene & Tropical Medicine
Biography to follow
Dr Nicholas Latimer
Reader in Health Economics, School of Health and Related Research, University of Sheffield
Nicholas is a health economist and a Yorkshire Cancer Research Senior Fellow. He studied Economics at the University of Nottingham, Health Economics at the University of York, and has a PhD in Health Economics from the University of Sheffield. He has worked as a health economist in academia and the pharmaceutical industry and has experience in the design and analysis of clinical trials and economic modelling.
His main research interests are in survival analysis for economic evaluation, and the use of causal inference in health technology assessment.
Direct - financial
June 2017 to November 2017: BMS consultancy fee received on three occasions for attending advisory board meetings. June 2017 - nivolumab for metastatic microsatellite instability high colorectal cancer; November 2017 – nivolumab for first line non-small cell lung cancer and small cell lung cancer; November 2017 – nivolumab for adjuvant melanoma.
January 2017 to December 2017: Pfizer consultancy fees received. Member of Pfizer’s global modelling advisory committee. In 2017 discussed avelumab for ovarian, gastric, NSCLC and merkel cell carcinoma. In April 2017 provided advice to Pfizer on a statistical analysis plan relating to mylotarg for acute myeloid leukaemia.
May 2017: Merck consultancy fee received for providing a training course on treatment switching adjustment methods.
August 2017: fee received from a consultancy for work done on a Tesaro product. Reviewed survival analysis undertaken by FIECON on niraparib for maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Note, contact and payment was solely with FIECON.
September 2017: Janssen consultancy fee received for providing a 0.5 day training course on survival analysis.
October 2017 to December 2017: Astra Zeneca consultancy fee received for giving advice on survival modelling for durvalumab as a monotherapy among patients with stage IIIB-IV NSCLC.
November 2017 to March 2018: Bluebirdbio consultancy fee received for attending an innovation panel meeting for the treatment of transfusion-dependent β-thalassemia (November 2017), and for attending an advisory board meeting on Lenti-D in Cerebral Adrenoleukodystrophy (March 2018).
May 2018: provided a training course to Pierre Fabre on treatment switching methods.
January 2019 to present: fee received from Pierre Fabre for advice on adjusting for treatment switching in the Beacon Study investigating Encorafenib + Cetuximab Plus or Minus Binimetinib in patients with BRAF V600E-mutant metastatic colorectal cancer.
May 2018 to present: provided modelling advice to Sirtex Medical UK for selective internal radiation therapy using microspheres (SIR-Spheres) for patients with locally advanced inoperable hepatocellular carcinoma.
November 2018 to March 2019: Bluebirdbio consultancy fee received for attending advisory board meetings on Lenti-globin for transfusion-dependent β-thalassemia and sickle cell disease and on Lenti-d for cerebral adrenoleukodystrophy.
January 2019: Sobi consultancy fee received for attending advisory board meeting on emapalumab for primary haemophagocytic lymphohistiocytosis.
March 2019: Atara Biotherapeutics consultancy fee received for attending advisory board meeting on tab-cel®, an allogeneic T-cell immunotherapy for patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disorder.
April 2019: Merck Sharp & Dohme Limited consultancy fee received for providing a one-day training course on survival analysis.
Direct - non-financial
September 2017 to November 2017: advised on modelling for enzalutamide in non-metastatic prostate cancer. Also gave advice to Astellas through the NICE Scientific Advice programme on enfortumab vedotin for urothelial carcinoma. No payment received.
January 2017 to present: data sharing agreements with the following companies, to aid my post-doctoral research fellowship:
- Roche - data from BRIM 3 trial (Vemurafenib for patients with unresectable stage IIIC or IV melanoma with V600 BRAF mutation) and data from the M77001 trial (trastuzumab for patients with HER2 positive metastatic breast cancer).
- Amgen - data from Study 20020408 (panitumumab for patients with metastatic colorectal cancer).
- Bohringher Ingelheim - data from LUX-Lung 1, LUX-Lung 3 and LUX-Lung 6. Afatinib for Stage IIIB/IV lung cancer.
No funding is involved in these agreements.
January 2017 to present: The University of Sheffield has received funding from BMS to conduct research into survival analysis methods, not product specific.
January 2017 to August 2017: The University of Sheffield received funding from Merck for analysing the pivotal trial of cladribine for Multiple Scelerosis. Work was completed in August 2017 although resulting papers are still being written.
Non-financial professional and personal
March 2019: currently on the project team for a project being carried out on the surrogate relationship between PFS and OS in cancer, funded by Takeda. The University of Sheffield receives the funding.
Dr Veline L'Esperance
Veline is an academic General Practitioner in South London and an NIHR Doctoral Fellow at Kings College London. She holds a Master of Public Health and a Master of Science in Healthcare Policy and Management.
Her current research uses econometric methods to investigate the relationship between the allocation of resources and healthcare outcomes in general practice. Her ongoing interests are in primary care health economics and health service research.
She teaches on the Master of Public Health (MPH) programme at Kings College London. She was previously a National Medical Director's Clinical Fellow and prior to studying medicine she worked in the pharmaceutical industry.
Professor Allyson Pollock
Director, Institute of Health and Society, Newcastle University
Allyson trained in medicine and is a public health physician and academic scholar. She is Director of the Institute of Health and Society in the Faculty of Medical Sciences, Newcastle University.
She has previously worked at University College London, the University of Edinburgh, and Queen Mary University of London, and was Director of Research and development at University College London Hospitals NHS Foundation Trust from 1998 to 2005.
Allyson’s current research is into access to medicines and appropriate medicines use, and pharmaceutical regulation and regulatory science, and the epidemiology of child and sports injury. She is well known for her active commitment, spanning more than two decades, to promoting universal public health care in the UK, and her expertise on marketisation and other aspects of health service reform.
Dr Stephen Smith, BSc MPhil MB BChir PhD MRCP
MRC Post-doctoral Clinical Research Fellow, University of Cambridge
Stephen is a clinical academic working at the University of Cambridge and EMBL-European Bioinformatics Institute. His clinical training is as a clinical pharmacologist and dermatologist at Addenbrookes in Cambridge.
Following a BSc in virology and PhD in Immuno-genomics from Edinburgh, he completed his medical degree in Cambridge, early clinical training at Addenbrookes and then MPhil from the Cambridge department of Applied Mathematics and Theoretical Physics. He went on to pursue an academic clinical career focused on applying bioinformatics to cancer biology. He has an ongoing interest in the application of computational modeling and machine learning techniques to healthcare datasets including to health economics and health technology. He joined committee B in 2017.
Professor Nicky J Welton BSc MSc PhD
Professor of Statistical and Health Economic Modelling, University of Bristol
Nicky graduated with a BSc in mathematics from Sheffield University, an MSc in statistics from University College London, and a PhD in mathematical biology from the University of Bristol. She is currently Professor of Statistical and Health Economic Modelling in the department of population health sciences at the University of Bristol. Here she leads the Multi-Parameter Evidence Synthesis research group, is Director of the departments Short Course Program, and Deputy Director of the Clinical Guidelines Technical Support Unit.
Her research interests include: methods for evidence synthesis in health technology assessment, network meta-analysis, extrapolating survival curves, bias adjustment in evidence synthesis, use of evidence in economic models, and value of information analysis.
Direct - financial
June 2015 to present: contributes a session (for which she receives payment) on evidence synthesis for an Association of British Pharmaceutical Industry master class entitled: “What makes a good submission to NICE”.
February 2019: received fees from the Association of the British Pharmaceutical Industry (ABPI) for delivering masterclasses on evidence synthesis.
Indirect - financial
January 2015 to September 2018: principle investigator for an MRS Methodology Research grant, in collaboration with Pfizer Ltd. Pfizer part fund a junior researcher on the project. The project is purely methodological and uses historical date on pain relief.
Principal Investigator for a research project part funded by the MRC and Pfizer Ltd. Pfizer part-funded a junior researcher until Dec 2018. The project is purely methodological, concerned with synthesis of dose-response and time-course information. The project used historical data on pain relief.
Mr Nigel Westwood
Nigel left school and joined the Royal Navy as an officer in 1975. After initial training he served on a number of ships including appointments as a bridge watch-keeping officer, gunnery officer, navigating officer, specialist warfare officer, second-in-command and as captain. On moving ashore he joined the staff of the Commander-in-Chief Fleet with responsibility for controlling naval operations around the world before moving to a new NATO headquarters where he worked on NATO policy and negotiating allocation of forces with nations.
After completing the prestigious Joint Service Defence College course he took up an appointment in the Ministry of Defence in London working on future equipment requirements.
In 1997 he showed the first signs of what subsequently proved to be Ulcerative Colitis and despite an intensive drug regime, his condition deteriorated forcing him to undergo a pan-proctocolectomy and obliging him to leave the Royal Navy in the rank of commander after 25 years service. He now owns and runs an information technology business.
He has been an active volunteer with a number of charities and organisations particularly Crohn's and Colitis UK since his diagnosis serving as a trustee and vice-chairman for a number of years before stepping back for personal reasons in 2010.
Professor Sarah Wild
Professor of Epidemiology, University of Edinburgh
Sarah did her medical training in London and Cambridge. Her postgraduate experience included general medicine and diabetes, general practice and public health medicine, a cardiovascular epidemiology fellowship at Stanford University and a PhD at the London School of Hygiene and Tropical Medicine.
Sarah has worked at the University of Edinburgh since 2002 and is now professor of epidemiology and an honorary consultant in public health at Lothian NHS Board. Her main interests are the epidemiology and prevention of diabetes and other non-communicable diseases and the use of routine data for research.
Direct - non-financial
2016 to present: on the steering group of the Scottish Study Group for Diabetes in the Young whose meetings are supported by educational grants from Novo Nordisk.
Non-financial professional and personal interest
2016 to present: as a member of the steering group for the Scottish Study Group for Care of Diabetes in the Young Sarah receives subsidised accommodation, subsistence and conference attendance for the bi-annual meetings of the group because the meeting is supported financially by Novo Nordisk.
Mr Peter Wheatley Price
Director of Market Access & Pricing, Takeda UK
Biography to follow.
Dr Stuart Williams
Consultant Radiologist, Norfolk and Norwich University Hospital
Stuart qualified in medicine from Oxford University and worked in a variety of medical jobs in Oxford, Birmingham and London before returning to Oxford to train in radiology. Since 2001 he has been a consultant radiologist at Norwich and honorary senior lecturer at Norwich Medical School. He has variously been head of training, radiology clinical director, RCR regional chair and Trust lead for audit and improvement.
Between 2010 and 2013, Stuart was one of the first cohort of NICE clinical fellows and was subsequently a member of the guideline development group around recognition and referral of suspected cancer (NG12).
Mr Tony Wootton
Tony is a retired secondary school headteacher. After graduating from Newcastle University he started his working life as an accountant before embarking on a teaching career which spanned nearly 30 years, working in Leeds, London and North Yorkshire.
Since retiring Tony has served on a number of NICE guideline development groups covering topics ranging from ‘anti-social behaviour and conduct disorders’ through to ‘achieving better access to urgent and emergency mental health care for children and young people’ and most recently ‘Suspected Neurological Conditions Recognition and Referral’.
Tony has been a member of the Lymphoma Association for a number of years since his own diagnosis of Non-Hodgkin Lymphoma in 2009. In recent years Tony and his wife have provided short break respite care to children and young people with learning difficulties.